IGF2 and cancer: In contrast to the many epigenetic alterations affecting IGF-II commonly found in cancers, actual genetic mutations in IGF-II appear to be relatively rare with 149 mutations in 24 different cancers listed in the Cancer Genome Atlas (https://portal.gdc.cancer.gov/), with a prevalence ranging from 7% in uterine endometrial carcinomas to less than 0.5% in most of the common cancers [6].